Please ensure Javascript is enabled for purposes of website accessibility

FDA Facilitating Use of Plasma From Recovered COVID-19 Patients to Treat Serious Cases

By Brian Orelli, PhD - Mar 25, 2020 at 3:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The plasma of those who have recovered contains antibodies to the novel coronavirus, which could help other patients fight it off.

On Tuesday, the Food and Drug Administration said it's facilitating access to the blood plasma of patients who have recovered from COVID-19. Because those patients have fought off disease, their plasma should contain antibodies to SARS-CoV-2, which causes it.

The agency outlined eligibility rules for donors, including that they should have been free of symptoms for at least 14 days and test negative for COVID-19. The FDA would also like their plasma to be tested for neutralizing antibodies to the virus, but the agency realized that may not always be possible.

The agency is also approving emergency Investigational New Drug (IND) Applications for individual patients. It's shooting for getting those emergency INDs through the process in 4 to 8 hours via email, and is also offering verbal authorizations over the phone if doctors need a response more quickly.

Typically INDs are cleared in 30 days for entire clinical trials and require extensive pre-clinical testing. But we're in an emergency situation, and plasma-based drugs have been found effective in treating other diseases, including primary immunodeficiency, where patients have a weakened immune system.

However, as the agency stated explicitly in a press release: "Although promising, convalescent plasma has not been shown to be effective in every disease studied. It is therefore important to determine through clinical trials, before routinely administering convalescent plasma to patients with COVID-19, that it is safe and effective to do so."

Nurse holding a woman's donated plasma

Image source: Getty Images.

Multiple companies taking the same approach

Earlier this month, Takeda Pharmaceuticals (TAK -0.25%) announced plans to develop a plasma-derived therapy, TAK-888, from patients who have recovered from the disease. Takeda already sells other plasma-derived therapies that are manufactured at the Georgia facility where TAK-888 will be produced.

Emergent BioSolutions (EBS 0.21%) is also developing plasma-based treatments for COVID-19, including COVID-HIG, which will be derived from recovered patients, and COVID-EIG , made from plasma taken from horses that were given the virus. Emergent BioSolutions, which specializes in fighting bioterrorism and emergent diseases, sells human-plasma products for smallpox vaccine complications and anthrax, as well as a horse-derived plasma treatment for botulism.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
EBS
$31.11 (0.21%) $0.07
Takeda Pharmaceutical Company Limited Stock Quote
Takeda Pharmaceutical Company Limited
TAK
$14.01 (-0.25%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.